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ABSTRACT
Organophosphates (OPs), used as insecticides and nerve agents, pose a severe threat to
military personnel and civilians because of their potency as inhibitors of acetylcholinesterase
(AChE). The OP insecticide phorate (rat oral LD50 1.4-3.7 mg/kg) is particularly toxic and could
be used as a chemical weapon. Unlike similar OPs, phorate exhibits an unusual delay in the
appearance of toxic signs in laboratory rats. Phorate has a more complex metabolism than most
OPs: activation to phorate-oxon (PHO), then sulfoxidation to PHO-sulfoxide (PHX) and then to
PHO-sulfone (PHS), which are increasingly more potent anticholinesterases. Additionally, PHO
exhibits a different oxime-mediated reactivation profile than the well-studied OP paraoxon (PXN)
which is also a diethyl phosphate. Two hypotheses, that PHO is bioactivated to its more potent
metabolites PHX and PHS in the brain, and that PHO utilizes an unorthodox ethoxy leaving group,
could help explain these differences between PHO and PXN. Analysis of OP scavenger
carboxylesterase inhibition in rat liver by phorate metabolites indicates poor inhibition efficacy by
PHX (IC 50: 420 nM) as compared to PHO and PHS (IC50: 20 or 32 nM, respectively); this could
support the hypothesis of an alternative leaving group. Computational modeling (docking,
molecular dynamics, quantum mechanics/molecular mechanics) is used to further determine the
plausibility of the alternative leaving group hypothesis. Finally, oximes, like FDA-approved 2PAM, can reactivate inhibited AChE, but 2-PAM is unable to penetrate the blood-brain barrier
(BBB). MSU’s novel substituted phenoxyalkyl pyridinium oximes (US patent 9,277,937) have
been shown to reactivate inhibited AChE in the brain in animal tests. In vitro results showed levels
of novel oxime AChE reactivation in rat brain preparations inhibited by PHO, PHX, or PHS that
are comparable to those of 2-PAM. Initial in vivo results showed increased 24-hr survival
compared to 2-PAM when novel oximes were administered following lethal doses of PHO in rats.
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MSU’s novel oximes may lead to better protection from phorate poisoning. (Support: NIH R21
NS108954)
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INTRODUCTION
Phorate, also known by the commercial name Thimet, is a highly neurotoxic chemical
compound commonly used as a pesticide both within the US and abroad. Phorate is classified as
an organophosphate (OP), a class of chemicals including other pesticides and nerve agents which
operate by inhibiting the enzyme acetylcholinesterase (AChE) (US EPA, 2006). This inhibition
leads to the buildup of the neurotransmitter acetylcholine (ACh) in synapses and neuromuscular
junctions, which can cause permanent brain damage and death in humans (Moyer et al., 2018).
Phorate itself is particularly toxic (rat oral LD50 1.4-3.7 mg/kg), and as such is classified as a
restricted use pesticide in the United States, resulting in limited access for civilian use (US EPA,
2006). However, phorate remains abundant in developing nations and is accessible within the
US, leading to concern that phorate’s inconspicuous agricultural nature combined with its
toxicity to humans make it a prime candidate for use as a chemical weapon by terrorists. This
study is thus motivated to analyze phorate’s properties as an anticholinesterase OP, as phorate is
poorly studied in comparison to other OP pesticides and exhibits a variety of unorthodox
behaviors. This behavior includes a delay in the onset of toxic signs in rat models following
phorate exposure. Such a delay could be used as a terrorist strategy to induce panic in an exposed
population. Additionally, phorate exhibits a different oxime mediated reactivation profile than
the OP paraoxon (PXN), despite both OPs being diethyl phosphates. Finally, this study analyzes
the effects of MSU’s novel substituted phenoxyalkyl pyridinium oximes (US patent 9,277,937),
on phorate metabolite-inhibited AChE, which may serve as a more effective therapy to combat
phorate exposure due to the novel oximes’ demonstrated ability to reactivate inhibited AChE in
the brains of intact animals (Chambers et al., 2016; Dail et al., 2019).
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Rather than directly producing inhibitory effects, phorate undergoes a specific
metabolism in order to generate toxic metabolites (Fig. 1) (Moyer et al., 2018). The IC50
(concentration needed to inhibit 50% of AChE in a sample), of phorate is over 100,000 nM,
indicating that phorate itself is not particularly inhibitory. Instead, phorate is bioactivated to a
more toxic metabolite, phorate-oxon (PHO) (IC50 650 nM), by a class of enzymes known as
cytochrome P450s (CYPs) (Chambers et al., 2018). PHO then may be further bioactivated by
CYPs to phorate-oxon sulfoxide (PHX) (IC50 500 nM), and again to phorate-oxon sulfone
(PHS) (IC50 350 nM). In comparison, the active metabolite of the pesticide parathion, PXN, has
an IC50 of 23 nM. However, it is hypothesized that the more toxic metabolites PHX and PHS
may be so reactive as to never escape the liver, which has very high CYP activity, indicating that
PHO may be the only phorate metabolite actively circulating in the body (Nebert et al., 2013).
Furthermore, CYPs in the brain may be capable of bioactivating PHO to PHX and PHS,
potentially leading to formation of phorate’s more toxic metabolites near critical target AChE in
the central nervous system. The formation of more toxic metabolites in the brain following
phorate exposure could help explain the observed delay in toxic signs following phorate
exposure.
AChE, phorate’s target, is an enzyme critical for neurological function in the body that is
responsible for hydrolyzing the neurotransmitter ACh into its component parts: acetic acid and
choline. During usual operation, ACh is hydrolyzed by interacting with AChE’s catalytic triad
located in the enzyme’s active site. However, during inhibition by an OP such as PHO, the OP
irreversibly binds to the serine group present in the catalytic triad, preventing ACh hydrolysis
(Colović et al., 2013). This leads to the buildup of ACh in synapses and neuromuscular
junctions, overstimulating them, which disrupts the function of the central and peripheral
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nervous systems. That disruption promotes the onset of SLUD (salivation, lacrimation, urination,
and defecation) symptoms and can lead to bradycardia, respiratory arrest, seizure, and death in
humans (Peter et al., 2014).
Following exposure to OPs, either in pesticide or nerve agent form, treatment usually
consists of a combination of atropine and an oxime reactivator. The drug atropine is an
anticholinergic muscarinic antagonist, reducing effects of overstimulation by reducing ACh
receptor activity. Oxime reactivators, however, are nucleophilic drugs intended to restore AChE
function by removing the inhibiting phosphoryl group from the OP-bonded serine. Currently, the
FDA approved oxime reactivator used for therapy following OP exposure is 2-PAM. However,
2-PAM has been shown to be ineffective at penetrating the blood-brain barrier (BBB), a highly
selective semipermeable membrane that prevents some typically polar solutes from entering the
extracellular fluid of the central nervous system (Abbott 2002; Chambers et al., 2016). This is
problematic for the current class of approved oximes, pyridinium oximes, as they carry a
permanent positive charge due to quaternary nitrogen in the pyridine ring. This is additionally
problematic for OP exposure treatment as OPs like PXN and PHO permeate the BBB, and
without oximes present, they can continue to wreak havoc on the central nervous system even
after the current oximes are introduced as treatment. However, MSU has developed novel
phenoxyalkyl pyridinium oximes (U.S. patent 9,277,937) that have demonstrated ability to cross
the blood-brain barrier and attenuate brain damage in rats (Fig 3.) (Dail et al., 2019). As PHO is
hypothesized to be bioactivated to its more toxic metabolites PHX and PHS in the brain, these
novel oximes’ ability to penetrate the BBB are even more critical when considering treatment for
phorate exposure.
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The exact interaction phorate’s metabolites have with AChE is currently unknown, but it
is hypothesized to be similar to PXN, a well-studied OP that operates by the traditional OP
mechanism of phosphorylating the active site serine with release of the group designated as the
“leaving group”. During the interaction, PXN undergoes a substitution reaction in which the
bond binding the central phosphate to its leaving group breaks, resulting in PXN’s diethyl
phosphate remaining irreversibly bound to the active site, inhibiting the enzyme (Kousba et al.,
2004). PXN and PHO are both diethyl phosphates (Fig. 2), and as such, PHO is expected to
follow a similar mechanism, binding to the active site serine while its sulfur-containing group
behaves as the leaving group, resulting in a similar diethyl phosphate group remaining bound to
the active site serine. However, PHO and PXN have exhibited different oxime reactivation
profiles. As oxime mediated reactivation efficacy should primarily be influenced by what
remains bound to the active site, PHO and PXN would be expected to exhibit similar reactivation
profiles if they utilized similar leaving groups. Therefore, PHO is hypothesized to utilize an
alternative leaving group, perhaps one of its ethoxy groups, during serine phosphorylation.
Exploring these hypotheses can be done in a variety of ways; however, for the purpose of
this study, phorate’s properties will be explored by analysis of its metabolites’ inhibitory profile,
oxime mediated reactivation profile, and binding characteristics. A metabolite’s inhibitory
profile, or its efficacy in inhibiting certain enzymes, can be tested in vitro by calculation of its
IC50s. Butyrylcholinesterase (BChE) and carboxylesterase (CbxE) are also serine esterases and
act as OP scavengers, or protective enzymes that can reduce OP toxicity by shielding more
important enzymes like AChE by being inhibited by and thus inactivating incoming OPs
(Masson and Lockridge, 2009; Hatfield et al., 2016). Comparing the differences between AChE,
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BChE, and CbxE sensitivity to metabolites of phorate can offer clues to phorate’s more complex
metabolic pathway and binding profile.
Additionally, a metabolite’s binding profile can be explored directly by computational
simulation. By utilizing computational methods such as molecular docking, molecular dynamics,
and quantum mechanics, PDB (Protein Data Bank) files representing the metabolite and its target
enzyme can be manipulated and analyzed to compute approximate binding locations in addition
to barrier heights, or energetic costs, of a given chemical reaction pathway (Case et al., 2018;
Morris et al., 2009). In this way, the feasibility of phorate metabolites utilizing an alternative
leaving group during AChE phosphorylation can be determined.
Finally, phorate’s oxime-mediated reactivation profile can be examined by analyzing
inhibited AChE reactivation efficacy assayed with various inhibitors (PXN, PHO, PHX, or PHS)
and reactivators (2-PAM or selections from MSU’s library of novel oximes). This difference can
be quantified in vitro by biochemical reactivation assay or by in vivo survivability study. In
either case, determining which oximes best protect against phorate will both bolster
understanding of phorate’s characteristics in addition to providing valuable information for how
to best protect against potential phorate attacks in the future.

FIGURE 1: Phorate Metabolism
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FIGURE 2: Phorate-Oxon (PHO, Left) and Paraoxon (PXN, Right) (Diethyl Phosphate Bolded)

FIGURE 3: MSU’s Novel Oxime Structures (Left, US patent 9,277,937) and 2-PAM Structure
(Right)
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METHODS
In vitro AChE, BChE, and CbxE Sensitivity
AChE, BChE, and CbxE sensitivity to phorate’s toxic metabolites (PHO, PHX, and PHS)
and PXN for comparison were assessed by calculation of the IC50 values for each respective
metabolite and enzyme combination. To do this, a range of metabolite concentrations intended to
induce 20% - 80% inhibition was established for each enzyme-metabolite combination (Table 1).
Each combination’s range was then assayed in a two-phase inhibition and analysis
spectrophotometric assay. All concentrations are listed as final.
Inhibition Phase: For each metabolite-enzyme combination, 15 of 20 test tubes containing
2 mL of 10-4 mL/mL rat serum homogenate in 0.05 M Tris-HCl buffer (37°C, 7.4 pH) were
incubated for 15 minutes at 37°C with various OP metabolite concentrations (Table 1). Two of
the remaining tubes were similarly incubated with either 0.1 mM eserine-sulfate, a specific
AChE and BChE inhibitor, or 0.01 mM PXN, a potent CbxE inhibitor, corresponding to the
enzyme being assayed. The final three tubes were incubated with ethanol vehicle and served as
uninhibited controls.
Analysis Phase: Each of the tubes was treated with either 1 mM acetylthiocholine
substrate (AChE), 1 mM butyrylthiocholine substrate (BChE), or 0.5 mM nitrophenyl valerate
(CbxE) and incubated for 15 minutes at 37°C. The reaction was then terminated by addition of
0.05% sodium dodecyl sulfate plus 5,5'-dithio-bis(nitrobenzoic acid) (DTNB; the chromogen)
(AChE or BChE) or 0.02% sodium dodecyl sulfate (CbxE). The absorbance was quantified by a
spectrophotometer at either 412 nm (AChE or BChE) or 405 nm (CbxE) (Ellman et al., 1961).
Absorbance values for each metabolite-inhibited sample were corrected by subtraction of eserine
sample absorbances, which served as blanks. They were then compared to uninhibited control
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sample absorbances to generate percent inhibition. At least three replications were performed for
metabolite-enzyme combination. IC50s were calculated for each combination by log-logit
transformation of observed percent inhibitions.

AChE

BChE

CbxE

PHO

5.62E-7 – 3.16E-6

3.16E-7 – 3.16E-6

1.00E-8 – 1.00E-7

PHX

1.78E-7 – 1.78E-6

1.00E-7 – 1.00E-6

1.78E-7 – 1.78E-6

PHS

5.62E-8 – 5.62E-7

3.16E-8 – 3.16E-7

1.78E-8 – 1.00E-7

PXN

5.62E-8 – 5.62E-7

5.62E-8 – 5.62E-7

5.62E-10 – 5.62E-9

TABLE 1: OP Concentration Ranges for AChE, BChE, and CbxE

In vitro AChE Reactivation Efficacy
In vitro AChE reactivation efficacy was assessed in rat brain homogenate by
spectrophotometric assay divided into three phases: inhibition, reactivation, and analysis. Each
assay featured 1 of 4 OP inhibitors (PXN, PHO, PHX, or PHS) and 5 oxime reactivators (2PAM, and MSU 1, 15, 20 and 55). All concentrations are listed as final.
Inhibition Phase: For each assay, 5 of 6 1.5mL microcentrifuge tubes containing 1 mL of
1 mg/mL rat brain homogenate were incubated for 15 minutes at 37°C with one of the following
OPs: 2.37 * 10-6 M PHO, 10-6 M PHX, 10-6 M PHS, or 10-7 M PXN. Concentrations were
chosen to yield 80-90% inhibition compared to ethanol vehicle. The remaining tube was
similarly incubated with ethanol vehicle to serve as an uninhibited control.

10

Reactivation Phase: Following inhibition, 100 μM of the following oximes were
incubated for 30 minutes at 37°C, each in its own respective inhibited sample: MSU 1, 15, 20 or
55 or 2-PAM, or oxime vehicle (dimethyl sulfoxide: ethanol; 1:1).
Analysis Phase: Each tube was diluted (0.25 mL of sample into 9.75 mL 0.05 M TrisHCl) and further portioned into 3 sub-samples (2 mL per sub-sample) and one 2 mL blank,
which was treated with 0.1 mM eserine sulfate. After 15 minutes, each tube was treated with 1
mM acetylthiocholine substrate and incubated for an additional 15 minutes at 37°C. The reaction
was then terminated by addition of 0.05% sodium dodecyl sulfate plus 5,5'-dithiobis(nitrobenzoic acid) (DTNB; the chromogen). The absorbance was quantified in a
spectrophotometer at 412 nm (Ellman et al., 1961; Chambers et al., 1988). Absorbance values for
each sample were corrected by subtraction of eserine sample absorbances. Absorbance values
were then compared to uninhibited control absorbances to generate percent inhibition. Percent
inhibition values from reactivated samples were then compared to the percent inhibition of the
unreactivated sample to generate percent reactivation. At least three replications were performed
for each OP.

In Vivo 24-Hour Percent Survival in Rats Following Lethal Dose of PHO
An LD99 dosage (2.5 mg/kg; SC) of PHO (dissolved in Multisol) was established that
was lethal within 24 hr to all rats treated with 0.65 mg/kg atropine (IM in saline). This dosage
was also lethal within 24 hr to a moderate number of rats treated with atropine at 0.65 mg/kg (IM
in saline) plus 2-PAM at 0.146 mmol/kg (human equivalent dosage for 3 autoinjectors; IM in
Multisol). Oximes in Multisol were administered (IM) at 0.146 mmol/kg (2-PAM molar

11

equivalent dosage). Antidote (atropine +/- oxime) was administered at time of seizure onset
(about 2 hours after PHO challenge). Rats were observed for the first 8 hours and 24-hour
survival was recorded.

Computational Analysis (Docking, Molecular Dynamics)
To generate and prepare the AChE-OP complex for simulation, the X-ray crystal
structure of the AChE (PDB code: 1F8U) was used. Partial atomic charges for PHO, PHX, and
PHS were fitted with RESP charges adapted from the RED Server at the HF/6-31G*. (Bayly et
al., 1993). Protonation states of all acidic and basic amino-acids residues were determined by the
surrounding environment under physiological pH conditions (pH 7.4) using the H++ server
(Gordon et at., 2005). Molecular docking calculations of the crystal structure were carried using
the Autodock4.2 (AD4) software program through the graphical user interface AutoDockTools
(ADT 1.5.4). The docking area was centered on the active site of the AChE and encompassed the
residues of the catalytic triad. Hence, 100 separate docking calculations were performed using a
Lamarckian Genetic Algorithm (Morris et al., 2009). This generated AChE-OP complexes for
PHO, PHX, and PHS. Finally, the lowest energy binding pose provided by preliminary docking
calculations was selected as the starting conformation for the subsequent molecular dynamics
simulation. The ff14SB AMBER force field was used to assign bonded and nonbonded
parameters to the protein. Hydrogen atoms were added to the PDB file via the LEAP module of
the AMBER18. The system was solvated in an octahedron box of TIP3P water for a minimum
distance of 10 Å on each side neutralized with sodium ions (Na+) (Maier et al., 2015; Jorgensen
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et al., 1983; Åqvist, 1990). Ligand parameters were adapted from the GAFF force field using
Antechamber (Wang et al., 2004; Wang et al., 2006).
MD simulations were then performed on each complex using the AMBER18 software
package (Case et al., 2018). The simulation was performed under periodic boundary conditions
and the long-range electrostatics were treated with the particle mesh Ewald method (Darden et
al., 1993). The system temperature was maintained by the Langevin dynamics with a collision
frequency of 1 ps-1 and the pressure was controlled by the Berendsen barostat with a pressure
relaxation time of 1 ps (Uberuaga et al., 2004; Berendsen et al., 1984; Ryckaert et al., 1977). A
cutoff distance of 12 Å was set for the nonbonded interactions and all covalent bonds that
involve hydrogen atoms were constrained by the SHAKE algorithm, which allowed for a
simulation timestep of 2 fs. Before the MD simulation, the system was energy minimized, first
by energy minimizing the water molecules and counter ions and then by energy minimizing the
whole system. After the initial minimization, the system was quickly heated up to 300 K in 100
ps using position restraints of 10.0 kcal mol–1 Å–2 for the residues of the protein and the
substrate. The system was further equilibrated using decreasing positional restraints, finishing
equilibration without any restraints. During the optimization and equilibration steps, the distance
between catalytic Ser199 hydroxyl oxygen and phosphorus atom of each substrate was restrained
to 3.2 Å and all restraints were released for the production run. Subsequently, the whole system
was simulated under an isothermal–isobaric (NPT) ensemble for 100 ns (300 K, 1 atm).
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RESULTS
In vitro AChE, BChE, and CbxE Sensitivity
AChE and BChE followed the expected trend of PXN being the most potent inhibitor
followed by PHS, then PHX, and finally PHO. In CbxE, PHO, PHS, and PXN were potent
inhibitors; however, PHX was a comparatively poor inhibitor, with IC50 values 2 orders of
magnitude greater than the other OPs.

Sensitivity of AChE, BChE, and CbxE to PHO, PHX,
PHS, and PXN
10000

IC50 (nM) (Logarithmic Scale)

PHO
PHX
1000

PHS
PXN

100

10

1
PHO
PHX
PHS
PXN

AChE
3867
372
152
106

BChE
1763
217
83
76
Enzyme

CbxE
31
1002
73
3

FIGURE 4: AChE, BChE, and CbxE IC50 (nM) of PHO, PHX, PHS, and PXN in Rat Serum
(Logarithmic Scale) (Error Bars used Standard Error; number of replications = 3)
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Computational Analysis (Docking, Molecular Dynamics)
Autodock4 generated 150 potential poses; the favorable poses were within the active site
gorge of AChE. Further simulation using AMBER18 found that each OP was well positioned to
interact with the catalytic triad of AChE (Serine 199, Histidine 433, and Glutamate 330).

FIGURE 5: Binding of PHO, PHX, and PHS (Top Left, Top Right, Bottom Middle,
respectively) to AChE (H: White, C: Cyan, O: Red, S: Yellow, N: Blue, P: Brown) (Images
Generated using VMD (Humphrey et al., 1996))
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In vitro AChE Reactivation Efficacy
Novel oximes MSU 1, 15, 20, and 55, and 2-PAM all provided some reactivation with
PHO, PHX, and PHS. Overall, 2-PAM proved to be the most effective reactivator across all
inhibitors except for PXN, which was most effectively reactivated by MSU 55.

Reactivation of Rat Brain Acetylcholinesterase Inhibited
by Phorate Metabolites or Paraoxon
Phorate-Oxon
Phorate-Oxon Sulfoxide
Phorate-Oxon Sulfone
Paraoxon

100.00

Percent Brain AChE Reactivation

90.00
80.00
70.00
60.00
50.00

40.00
30.00
20.00
10.00
0.00
2-PAM

Oxime 1

Oxime 15
Oxime

Oxime 20

Oxime 55

FIGURE 6: Percent reactivation following treatments of 2-PAM or MSU 1, 15, 20, or 55 (Error
Bars used Standard Error; number of replications = 3)
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In Vivo 24-Hour Percent Survival in Rats Following Lethal Dose of PHO
Following lethal doses of PHO, preliminary data show greater survivability in rats treated
with MSU 15 and 55 over 2-PAM and MSU 20.

24-Hour Percent Survival in Rats Following Lethal
Dose of PHO
100

90
80
70

%

60
50
40
30
20
10
0
No
Treatment

2-PAM

Oxime 15

Oxime 20

Oxime

FIGURE 7: In vivo 24-Hour Percent Survival
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Oxime 55

DISCUSSION
In vitro AChE, BChE, and CbxE Sensitivity
Stoichiometric OP scavengers like BChE and CbxE protect AChE by covalently binding
to OPs, preventing them from causing further inhibition. This study shows that metabolites of
phorate are inhibitory to BChE and CbxE, and as such, we can expect those enzymes to produce
protective effects. However, BChE and CbxE display surprisingly different inhibitory profiles in
relation to the toxic metabolites of phorate. First, BChE exhibits a similar inhibition profile to
AChE with PHO being inhibitory, PHX being more inhibitory, PHS being even more inhibitory,
and PXN being the most inhibitory. As BChE and AChE are both cholinesterases, have very
similar structures, and utilize similar – but not identical – active sites, it is no surprise that the
two enzymes follow very similar inhibition trends (Chatonnet and Lockridge, 1989). However,
CbxE exhibited a drastically different inhibitory profile, with PHX being weakly inhibitory
compared to the other OPs, PHS being an order of magnitude more inhibitory than PHX, PHO –
the parent compound of PHX and PHS – being even more inhibitory, and PXN being the most
inhibitory, nearly 3 orders of magnitude more so than PHX. CbxE, while structurally similar to
AChE and likely inhibited by the same process of covalent bonding to the active site serine, is
not a cholinesterase, and as such is not expected to act in the exact same manner as AChE and
BChE (Tsurkan et al., 2013). However, CbxE’s failure to follow the general trend of phorate
becoming more inhibitory as it is further bioactivated is a clear deviation from the norm.
This deviation could be the result of a variety of factors, including the previously
hypothesized utilization of an alternative leaving group, as slight changes in active site chemistry
(AChE vs CbxE) could cause different metabolites (PHO vs PHX) to utilize different leaving
groups during inhibition. This is not guaranteed, however, as the sulfoxide group distinguishing
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PHX from PHO could drastically change the binding efficacy when interacting with CbxE’s
active site as opposed to AChE. In either case, metabolites of phorate interact with CbxE in a
way that is inherently different than with AChE and BChE.
Furthermore, CbxE’s unorthodox inhibitory profile could alter its efficacy as a phorate
metabolite scavenger and thus phorate’s general metabolism. In particular, PHXs failure to
effectively inhibit CbxE as compared to similar OPs could indicate that PHX does not interact as
readily with CbxE, limiting its potential as a PHX stoichiometric scavenger. However, as CbxE
is 50% inhibited by PHO at a concentration 2 orders of magnitude lower than AChE and BChE,
distribution of phorate metabolites may only readily occur in regions of the body lacking high
levels of protective CbxE. In humans, CbxE is readily expressed in the liver but is largely absent
in the blood and brain (Hatfield et al., 2016). This disparity could limit phorate’s inhibitory
activity until phorate or PHO reaches the brain, contributing to both the observed delay in toxic
signs and the hypothesized bioactivation of phorate to its more toxic metabolites in the brain.
Additionally, CbxE circulates in the blood in rat models, potentially amplifying the delay even
further in this study’s in vivo models (Hatfield et al., 2016).

Computational Analysis (Docking, Molecular Dynamics)
Computational modeling results indicate what was expected of the traditional OP
inhibition pathway: that PHO, PHX, and PHS energetically favor the active site gorge of AChE,
and that they naturally position themselves to interact with AChE’s catalytic triad. More
important; however, are the poses that have been generated thus far by docking and molecular
dynamics, which will be used to begin quantum mechanical analysis in order to generate barrier
heights for alternative leaving groups. While this crucial quantum mechanical works remains to
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be done, these first steps provide necessary sanity checks as to phorate metabolites’ action and
pave the way for future progress in determining the energetic feasibility of the alternative leaving
group hypothesis.

In vitro AChE Reactivation Efficacy
In reactivating AChE inhibited by phorate metabolites, 2-PAM consistently achieved the
greatest level of reactivation in vitro. However, MSU’s novel oximes achieved comparable levels
of reactivation, indicating that they are also capable of restoring AChE function. Additionally,
AChE inhibited by more potent inhibitors – inhibitors with lower IC50s – were more difficult to
reactivate for all tested oximes than AChE inhibited by their less potent counterparts with the
notable exception of PXN. First, this trend serves as more evidence of the differences between
PXN and phorate metabolite reactivation profiles. Furthermore, it indicates that the sulfoxide and
later sulfone group gained during CYP bioactivation distinguishing PHX and PHS from PHO not
only make the bioactivated compounds more inhibitory, but they also make the resulting OPenzyme complex less susceptible to oxime nucleophilic attack. This indicates that the presumed
leaving sulfur-containing group for phorate metabolites may interact with the OP-enzyme
complex after covalent bonding of the OP to the serine; this assumption arises from the chemical
structure of that group being the only observable difference between PHO, PHX, and PHS
reactivation. That, in turn, lends more credence to the hypothesis of metabolites of phorate
utilizing an alternative leaving group, distinguishing them from similar OPs.

In Vivo 24-Hour Percent Survival in Rats Following Lethal Dose of PHO
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It is important to note that the data collected on in vivo survivability in rats are
preliminary, as further testing has not been attempted due to the difficulties of obtaining
consistent repetitions resulting from the observed delay in the onset of toxic signs. However, the
data that have been collected indicate that MSU’s novel oximes, specifically MSU 15 and 20,
promote greater survivability than FDA approved 2-PAM. As in vitro data indicated that 2-PAM
was a more effective reactivator than MSU’s novel oximes, a disparity exists between in vitro
reactivation efficacy and survivability. As MSU’s novel oximes have been shown to penetrate
the BBB (Chambers et al., 2016), survivability is likely increased by reactivation of rat AChE
located in the brain. Protecting the brain is a critical step in combating any OP poisoning;
however, as phorate is hypothesized to be bioactivated to its more toxic metabolites in the brain,
the capability of oximes to penetrate the brain is perhaps even more important when combating
phorate poisoning.

21

CONCLUSION
This study was designed to analyze various properties of phorate’s metabolites in order to
better understand the toxic pesticide’s characteristics should it ever be used as a chemical
weapon. While more analysis is needed to draw a clearer picture of those metabolites’ binding
action and metabolism, there are several conclusions that can be drawn from this study that help
both explain phorate’s unorthodox behavior and provide clues as to how to best combat it.
First, BChE and CbxE were shown to be inhibited by various concentrations of PHO,
PHX, and PHS, indicating that these traditional stoichiometric OP scavengers play a part in
protecting AChE during phorate exposure. This understanding will assist in the interpretation of
phorate metabolite inhibition of AChE among different tissue samples with various
concentrations of protective enzyme, in addition to predicting differences between human and rat
models.
Furthermore, as indicated by computational modeling, phorate’s metabolites likely follow
the traditional pathway of binding to the active site serine during AChE inhibition. However,
given the variety of inhibition and reactivation profiles exhibited by PHO, PHX, PHS, and PXN,
the ‘assumed leaving group’ clearly plays a large role in characterizing the behavior of each
individual metabolite, whether it is confirmed to be the true leaving group or not.
As for combating phorate poisoning, MSU’s novel oximes have been shown to be
effective, if not more effective, than 2-PAM, at reactivating phorate metabolite-inhibited rat
brain AChE in vitro. Additionally, preliminary in vivo data support the efficacy and importance
of BBB penetrating novel oximes when combating phorate poisoning.
While this study does not provide evidence that strongly supports the two proposed
hypotheses – that phorate is bioactivated to its more toxic metabolites in the brain and that PHO
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utilizes an alternative leaving group – it does provide data that are consistent with both
hypotheses and could lead to further support if more analyses, specifically quantum mechanical
and in vivo, are completed.
Ultimately, this study demonstrates the complexity of phorate’s biochemistry and the
need for better understanding of its variety of profiles and behaviors. Finally, it emphasizes the
potential value of brain penetrating oximes when combating phorate poisoning, as protection of
the brain remains a crucial aspect of combating OP exposure, potentially even more so with
regard to phorate.
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